macular oedema

Also found in: Dictionary, Thesaurus.
Related to macular oedema: Macular edema

macular oedema

Retinal thickening due to the accumulation of fluid, which occurs in diabetic retinopathy, visualised by a binocular slit lamp or stereoscopic fundus photography. While macular oedema has few visual consequences, other than distortion of central vision, it is often accompanied by hard exudates, which are associated with loss of vision.

Laser photocoagulation may be used to manage branch retinal vein occlusion (BRVO); it is ineffective for central retinal vein occlusion (CRVO).

oedema, cystoid macular (CMO) 

Oedema and cyst formation of the macular area of the retina. It may occur as a result of, or be associated with, systemic vascular disease, retinal vein occlusion, diabetic retinopathy, uveitis, hypertensive retinopathy, retinitis pigmentosa and following some ocular surgery such as vitreoretinal, photocoagulation, glaucoma procedures and especially cataract surgery. When cystoid macular oedema follows cataract surgery it is called the Irvine-Gass syndrome and it is sometimes accompanied by intraoperative vitreous loss or vitreous adhesion to the iris or to the corneoscleral wound. Visual acuity is affected initially but recovers in the majority of cases. In some cases antiinflammatory therapy may help in restoring visual acuity and in other cases the vitreous adhesion may be disrupted with a Nd-Yag laser.
References in periodicals archive ?
Conclusion: Cystoid macular oedema after phacoemulsification was equally present in both diabetics and non-diabetics without any retinopathy.
Diabetic macular oedema tends to be a chronic disease.
Methods: This quasi-experimental study was conducted at Layton Rahmatulla Benevolent Trust, Lahore, Pakistan, from October 2014 to March 2015, and comprised eyes of patients with refractory macular oedema.
Had macular oedema due to diabetic retinopathy, retinal venous occlusion, or postsurgical macular oedema (Irvine-Gass syndrome).
Bayer HealthCare member of the executive committee and head of Global Development, Joerg Moeller, stated that the approval of the product in Europe in this important indication is great news for the increasing number of patients suffering from visual impairment due to diabetic macular oedema.
Professor Carole Longson (pictured), health technology evaluation centre director at NICE, said: "Around 336,000 people with diabetes in the UK have diabetic macular oedema.
Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema.
2) The most common cause of visual impairment in diabetic retinopathy is macular oedema.
Objective: To determine the anatomical and functional improvement in eyes with diffuse macular oedema after modified mild macular grid laser.